AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03837548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with Neurofeedback
Description: Neurofeedback the brain activities by Magnetoencephalography
Study NCT03837548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The other Training with Neurofeedback
Description: Neurofeedback the brain activities by Magnetoencephalography
Study NCT04377282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: Cooked buckwheat
Study NCT04377282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Cooked couscous
Study NCT00648765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agrylin® Capsules 1 mg
Description: 1mg, single dose fed
Study NCT00629382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymyxin B immobilized fiber column
Description: Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
Study NCT00629382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional medical therapy in the ICU
Description: Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
Study NCT00629382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional medical therapy in the ICU
Description: Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
Study NCT00368212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation response training
Description: The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
Study NCT00368212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational counseling
Description: Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
Study NCT05611944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrigation and suction through subcutaneus drains
Description: Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
Study NCT01934101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-5154
Description: CHR-5154
Study NCT01934101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02223208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro-CHOEP-21 (PHASE I)
Description: Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)
Study NCT02223208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro-CHOEP-21 (PHASE II)
Description: Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)
Study NCT03826849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia Coach
Description: Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
Study NCT01233076 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Commercially marketed, spherical contact lens for daily wear, daily disposable use
Study NCT01233076 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon B contact lens
Description: Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
Study NCT01304576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological testing
Description: Experimental test about orientation agnosia and standard neuropsychological tests.
Study NCT01304576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Experimental test about orientation agnosia and standard neuropsychological tests.
Study NCT01304576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Cerebral MRI
Study NCT04377282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-3
Description: Water
Study NCT01304576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cerebral MRI
Study NCT04179864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Study NCT04179864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone/prednisone
Description: 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
Study NCT04179864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: enzalutamide 160 mg (four 40 mg capsules) orally once daily
Study NCT04179864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: enzalutamide 160 mg (four 40 mg capsules) orally once daily
Study NCT00157209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
Study NCT00157209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
Study NCT02835196 — intervention group
Intervention type: DEVICE
Intervention: Optical Elastography
Description: To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
Study NCT05274256 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant placement with simultaneous soft tissue augmentation
Description: implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
Study NCT02835196 — intervention group
Intervention type: OTHER
Intervention: Visual Assessment
Description: Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
Study NCT04600531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants.
Study NCT03250182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
Study NCT01427426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: All Greens
Description: All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
Study NCT01427426 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Formulation
Description: The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
Study NCT04600531 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants.
Study NCT04600531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)
Description: HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS).
Study NCT01644682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITN
Description: Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
Study NCT01690702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT01690702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT01690702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study NCT01690702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01690702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT04600531 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)
Description: HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS).
Study NCT01690702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02769910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin 24 Hours
Description: Dermal patches for transdermal application of Capsaicin, applied for 24 hours
Study NCT04240782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and hands on cooking classes for parents and their children
Description: The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
Study NCT04240782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce allocations
Description: Participants will also receive a produce allocation from a local farm during each session of the class.
Study NCT00511706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Intravitreal injection of dexamethasone 700 µg at Day 1.
Study NCT00511706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 500 µg at day -30 and Day 7-14.
Study NCT00511706 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab 500 µg at day -30 and Day 7-14.
Study NCT00511706 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Sham needle-less injection administered in the study eye at Day 1.
Study NCT00863564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caseine
Study NCT00863564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod
Study NCT00863564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Study NCT00863564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Isolate
Study NCT03980665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
Study NCT03235674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity stair climbing exercise
Description: High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
Study NCT02967393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ccIIV4
Study NCT02967393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IIV4
Study NCT04409132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
Study NCT03781310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
Study NCT03781310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
Study NCT00635193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: M200 (Volociximab)
Description: 7.5 mg/kg, IV infusion every week until disease progression
Study NCT00635193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
Study NCT00635193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: M200 (Volociximab)
Description: 15 mg/kg, IV infusions every week until disease progression
Study NCT00635193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: M200 (Volociximab)
Description: 15 mg/kg, IV infustions every other week until disease progression
Study NCT05726617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar Intervention
Description: 8 weekly sessions of 60 minutes.
Study NCT03808480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA and Nivolumab
Description: Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1\~4, 1cycle=21days) Nivolumab 360 mg/IV C2\~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
Study NCT01308385 — intervention group
Intervention type: OTHER
Intervention: Conditioned pain modulation
Description: When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
Study NCT04084652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion
Description: The ingestion of mycoprotein
Study NCT04027582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: didactic teaching and simulator practice
Description: the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
Study NCT01391260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
Study NCT04308668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
Study NCT04308668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
Study NCT03563989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Stent (PCI)
Description: Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
Study NCT03563989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Stent (PCI)
Description: Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
Study NCT03693846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion per institutional guidelines and the Package Insert
Study NCT03693846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion per institutional guidelines and the Package Insert
Study NCT04485871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.